ライフサイエンスコーパス: substance abuse

1 ADHD), aggression, post-traumatic stress and substance abuse.

2 brain to other drugs and prime it for future substance abuse.

3 e health, mental health, HIV, and alcohol or substance abuse.

4 ptic plasticity, and have been implicated in substance abuse.

5 s a nexus of frustration, physical pain, and substance abuse.

6 ol or other drugs highlight threats posed by substance abuse.

7 r the development of anxiety, depression and substance abuse.

8 environmental experiences such as stress and substance abuse.

9 ing, response disinhibition, aggression, and substance abuse.

10 current history of cocaine or other illicit substance abuse.

11 sity, maternal prenatal stress, and lifetime substance abuse.

12 ss high rates of psychiatric comorbidity and substance abuse.

13 caffold for development into a treatment for substance abuse.

14 in a number of complex disorders, including substance abuse.

15 d in diverse psychiatric disorders including substance abuse.

16 in individuals with a history of alcohol or substance abuse.

17 for treatment of stress-triggered relapse in substance abuse.

18 rate high comorbidity with chronic pain) and substance abuse.

19 lity measures that have been associated with substance abuse.

20 the Northeast, and history of depression or substance abuse.

21 cesses, as well as psychiatric disorders and substance abuse.

22 itical in the etiology of mood disorders and substance abuse.

23 tem (CNS), including Parkinson's disease and substance abuse.

24 markers and/or therapeutic targets for human substance abuse.

25 be damage and behavioral disorders including substance abuse.

26 striatal reward processing in the absence of substance abuse.

27 ire interventions to discourage this form of substance abuse.

28 and other disorders, as well as features of substance abuse.

29 rs (AUDs) constitute the most common form of substance abuse.

30 and is discussed as a key process underlying substance abuse.

31 ute to the aetiology of major depression and substance abuse.

32 ower rates of justice-system involvement and substance abuse.

33 f anxiety disorders, depression and comorbid substance abuse.

34 on may need review in patients with comorbid substance abuse.

35 s in medical specialties, mental health, and substance abuse.

36 lopment of anxiety, depression, and comorbid substance abuse.

37 ificance with incision length and history of substance abuse.

38 but so were somatic diseases, pregnancy, and substance abuse.

39 minorities, but less likely to abstain from substance abuse.

40 flect vulnerability of prodromal patients to substance abuse.

41 , facilitating behavioural reinforcement and substance abuse.

42 anxiety disorders, depression and co-morbid substance abuse.

43 sed risk for maladaptive outcomes, including substance abuse.

44 disorders including depression, anxiety, and substance abuse.

45 have shown promise in preclinical models of substance abuse.

46 eation in severely suicidal patients without substance abuse.

47 ease risk for maladaptive outcomes including substance abuse.

48 rable and individuals with AN protected from substance abuse?

49 based rates of unauthorised leave (2.4%) and substance abuse (1.6%) were low.

50 5) but decreased slightly when adjusting for substance abuse (1.71; 1.60-1.82).

51 disease (2.23; 2.08-2.39), and those without substance abuse (1.96; 1.82-2.11).

52 legal issues (+2 points), and prior illicit substance abuse (+1 point).

53 mental and behavioural disorders (including substance abuse; 21.5% [95 UI 17.2-26.3] of YLDs), and m

54 3.8% died prematurely) and those with solely substance abuse (6.2%) compared with those without comor

55 to initiate ART (94.7%) or had uncontrolled substance abuse (66.0%).

56 uthorised leave were 5.9% and 98.4%; and for substance abuse 8.1% and 99.0%.

57 When compared with those with no substance abuse, abusing all three substances was associ

58 ly-history negative (FHN, N=31) healthy, non-substance-abusing adults completed an fMRI Go/No-Go task

59 Alcohol or substance abuse after transplantation is associated with

60 including long-term opioid therapy or active substance abuse, age 65 years or older, and sleep apnea

61 d social support; (2) limited cognition; (3) substance abuse (alcohol and drug); (4) severe psychiatr

62 itions, recent major surgery, and history of substance abuse, alcohol abuse, and self-harm/suicide we

63 obsessive-compulsive disorder, anorexia, or substance abuse), along with their mates.

64 /3) receptors, may increase vulnerability to substance abuse, although whether this phenotype confers

65 divided about previous psychiatric illness, substance abuse and abdominal surgery.

66 Substance abuse and addiction are associated with an app

67 Substance abuse and addiction is a significant contempor

68 f illness, higher rates of lifetime comorbid substance abuse and anxiety disorder, more antisocial pe

69 rior treatment of a psychiatric condition or substance abuse and attention-deficit/hyperactivity diso

70 nd memory, pain sensation, fear and anxiety, substance abuse and cell death.

71 o a number of behavioral problems, including substance abuse and delinquent behaviors.

72 ecific etiological influences on measures of substance abuse and dependence.

73 ll other mental health conditions, including substance abuse and eating disorders, seem to be exacerb

74 s may help explain how stress contributes to substance abuse and how it can disinhibit automatic beha

75 ains (employment, education, marital status, substance abuse and income), each with a minimum of 0 an

76 Substance Abuse and Mental Health Services Administratio

77 s significantly influence susceptibility for substance abuse and mood disorders.

78 nucleus accumbens is critically involved in substance abuse and motivation, we sought to determine w

79 promising therapeutics for the treatment of substance abuse and neuropsychiatric disorders.

80 ine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.

81 , specially compared with those referred for substance abuse and personality disorders.

82 by the model included both well-known (e.g., substance abuse and psychiatric disorders) and less conv

83 impaired decision-making-typified by chronic substance abuse and relapse-observed after drug use.

84 increase the susceptibility for the onset of substance abuse and related psychiatric disorders.

85 evaluate the association between recipient's substance abuse and renal transplant access in patients

86 ive responding, such as ADHD, mania, chronic substance abuse and schizophrenia.

87 ons for a range of research lines, including substance abuse and stress, both research domains in whi

88 Environmental factors, including substance abuse and stress, cause long-lasting changes i

89 triatal CREM mediates impulsivity related to substance abuse and suggest that CREM and its regulated

90 re EHR and PRO for capture of depression and substance abuse and their relationship to adherence to a

91 exposure predicts negative outcomes such as substance abuse and traumatic stress disorders.

92 Subsequent incidents of substance abuse and unauthorised leave were coded indepe

93 validity of its specific risk estimates for substance abuse and unauthorised leave.

94 As a consequence, substance abuse and/or acute psychiatric problems are st

95 significantly so for those with co-occurring substance abuse and/or dependence.

96 s (such as anxiety, adjustment reactions, or substance abuse); and 495 (52%) had no mental health dia

97 but modestly related to persistence of mood, substance abuse, and anxiety disorders.

98 disorder, schizophrenia-spectrum disorders, substance abuse, and anxiety or somatoform disorders).

99 ected services across medical, mental health/substance abuse, and court/social service systems.

100 eased risk for recurrence, suicide attempts, substance abuse, and functional disability.

101 r adjustment for hepatitis C, renal disease, substance abuse, and hemoglobin level (HR, 1.25; 95% CI,

102 etime family history of bipolar disorder and substance abuse, and less history at baseline of severe

103 us psychological disorders are comorbid with substance abuse, and noradrenergic signaling in the bed

104 tion factors have been implicated in cancer, substance abuse, and other pathological conditions.

105 rental maladjustment (violence, criminality, substance abuse, and psychopathology), as well as econom

106 lence and other data on depression, anxiety, substance abuse, and psychotic syndromes, with emphasis

107 ed with drug abuse terms such as dependence, substance abuse, and respiratory depression).

108 ed higher rates of anger attacks/aggression, substance abuse, and risk taking compared with women.

109 n, diabetes, malignancies, mental disorders, substance abuse, and road injuries.

110 iatric diseases, including major depression, substance abuse, and schizophrenia.

111 to account as well as concomitant alcohol or substance abuse, and systemic shock.

112 ne line between therapeutic intervention and substance abuse, and this point is clearly exemplified i

113 ighly prevalent disorders (major depression, substance abuse, anxiety disorders, and posttraumatic st

114 gia (aOR 1.81, 95% CI 1.49-2.19, p < 0.001), substance abuse (aOR 1.72, 95% CI 1.65-1.79, p < 0.001),

115 Alcohol and substance abuse are common and may lead to a need for so

116 Sleep disorders and substance abuse are highly comorbid and we have previous

117 tions between socioeconomic status (SES) and substance abuse are sometimes positive, the poor are som

118 logy, social support, medical adherence, and substance abuse, are emphasized in advanced heart failur

119 includes measures of depression (PHQ-9) and substance abuse (ASSIST).

120 sed program was psychological treatments for substance abuse, associated with an HR of 0.75 (95% CI,

121 with a history of repeated social stress to substance abuse behaviors.

122 e drug-seeking and drug-taking are important substance-abuse behaviors that have been linked to alter

123 aving in patients with HIV, homelessness, or substance abuse, but not in others.

124 atterns, for example concerning injuries and substance abuse, cancer, and osteoporosis.

125 4.5% decline in trauma but a 35% increase in substance abuse cases during the COVID-19 period.

126 ts, temporary housing (homeless, shelter, or substance abuse center) was the only factor associated w

127 h were high in those with any psychiatric or substance abuse comorbidity (3.8% died prematurely) and

128 isk increase was minimal in patients without substance abuse comorbidity (adjusted odds ratio, 1.3; 9

129 he risk was mostly confined to patients with substance abuse comorbidity (adjusted odds ratio, 6.4; 9

130 marital and immigrant status) and mediators (substance abuse comorbidity) were measured at baseline.

131 medicine and family medicine: 1) integrating substance abuse competencies into training, 2) assigning

132 implicated in numerous neuropsychiatric and substance abuse conditions, but their spectral overlap w

133 s care for patients around mental health and substance abuse conditions, health behavior change, life

134 diagnostic categories assessed, psychoactive substance abuse conferred the highest risk for all-cause

135 Persons with chronic mental illness and/or substance abuse constitute 22% of the US population yet

136 recent research on the relationship between substance abuse, crime, violence and mental illness, and

137 wn to be associated with poor ART adherence (substance abuse; depression).

138 adjusting for co-occurring mental health and substance abuse diagnoses in follow-up regression models

139 F are associated with mechanism-of-action of substance abuse disorder for several marketed drugs (suc

140 ning (MFF) cluster (parental mental illness, substance abuse disorder, and criminality; family violen

141 [aOR], 1.35; 95% CI, 1.21-1.49), alcohol and substance abuse disorders (aOR, 1.34; 95% CI, 1.05-1.72)

142 Substance abuse disorders are linked to alteration of ci

143 the comorbidity between eating disorders and substance abuse disorders is high.

144 BN and those with substance abuse disorders may share dopamine D2 receptor

145 (22.3%-60.4%) of participants with 12-month substance abuse disorders received treatment for substan

146 exists a range of affective, psychotic, and substance abuse disorders that have been associated with

147 on (alcoholism) is one of the most prevalent substance abuse disorders worldwide.

148 eatment of sleeping disorders, bupropion for substance abuse disorders, and cannabinoids for epilepsy

149 predefined groups of psychiatric disorders (substance abuse disorders, schizophrenia, mood disorder,

150 estigated included organic mental disorders, substance abuse disorders, schizophrenia, mood disorders

151 cocaine addiction and a DSM-V criterion for substance abuse disorders, the molecular adaptations pro

152 tions for development of strategies to treat substance abuse disorders.

153 ders, but less likely to have behavioral and substance abuse disorders.

154 nt avenue for advancing our understanding of substance abuse disorders.

155 attention-deficit hyperactivity disorder and substance abuse disorders.

156 cocaine addiction and a DSM-V criterion for substance abuse disorders.

157 veloping neuropsychiatric disease, including substance abuse disorders.

158 Tolerance is a DSM-V criterion for substance abuse disorders.

159 iseases with multiple phenotypes such as the substance abuse disorders.

160 pain management, inflammation, obesity, and substance abuse disorders.

161 play important roles in depression, anxiety, substance abuse, emesis, inflammatory pain, spinal nocic

162 strongly linked prior to a possible onset of substance abuse, emphasizing their potential role in the

163 lthough depression frequently co-occurs with substance abuse, few individuals entering substance abus

164 mental health factors with other risks (eg, substance abuse, financial problems, relationship proble

165 MBASE searches (1966 to June 2008), national substance abuse guidelines from the United States and ot

166 Siblings of patients with depression and substance abuse had significantly increased fecundity (F

167 Patients with psychiatric diseases and/or substance abuse have an increased risk for hepatitis C v

168 o exclude tuberculosis, and in patients with substance abuse having smear-negative specimens to exclu

169 tion, peripheral arterial disease, epilepsy, substance abuse, heart failure, nonmetastatic cancer, me

170 Substance abuse history was the strongest predictor of O

171 Three percent had an alcoholism or substance abuse history, 6.4% had hepatitis B and/or C,

172 gender, education, schizophrenia diagnosis, substance abuse history, and geographic region.

173 f systemic and CNS inflammation in aging and substance-abusing HIV populations.

174 eive HIV care in the VA have higher rates of substance abuse, homelessness and unemployment than indi

175 ealth, including missed appointments, active substance abuse, homelessness, and unemployment are asso

176 most prevalent psychosocial risk factor was substance abuse in 1941 (12.6%) recipients.

177 findings may contribute to "protection" from substance abuse in AN.

178 Improved treatment for substance abuse in forensic psychiatric patients and oth

179 Impulsivity shares high comorbidity with substance abuse in humans, and high impulsivity (HI) in

180 ental milestones, and later vulnerability to substance abuse in juvenile nonhuman primates.

181 A higher prevalence of chronic diseases and substance abuse in low-SES individuals versus high-SES i

182 Substance abuse in mentally ill forensic psychiatric pat

183 mmendations focused on improving training in substance abuse in primary care residency programs in in

184 strate for impulsive-antisocial behavior and substance abuse in psychopathy.

185 unction may contribute to the comorbidity of substance abuse in schizophrenia.

186 Recreational drug use leads to compulsive substance abuse in some individuals.

187 This review focuses on alcohol and substance abuse in the context of solid-organ transplant

188 rm cigarette smoking and problems with other substance abuse in this population.

189 circadian clock can predispose or exacerbate substance abuse in vulnerable individuals.

190 luding HIV, AIDS, severe mental illness, and substance abuse) in the United States.

191 income inner-city communities, and engage in substance abuse, including intravenous and crack cocaine

192 Substance abuse increases an individual's vulnerability

193 nal activity, mental health, abstaining from substance abuse, interpersonal functioning, and parentin

194 Substance abuse is a major barrier in eradication of the

195 Substance abuse is a pressing problem with few therapeut

196 sociated neurocognitive disorders (HAND) and substance abuse is known to accelerate HIV disease progr

197 such as diet, physical activity, sleep, and substance abuse; it also reflects stable epigenetic modi

198 and suggest that a long duration of illness, substance abuse, low weight, and poor psychosocial funct

199 Vulnerability to depression, and perhaps substance abuse, may be preserved by balancing selection

200 Substance abuse, medical co-morbidities, and low (<15) M

201 increased rates of certain types of cancer, substance abuse, mental health conditions, infections, a

202 bstance use disorder in some youngsters, and substance abuse might complicate the subsequent course o

203 of MSM risk-taking (e.g., poverty, sex work, substance abuse, misconceptions about transmission, stig

204 Composite International Diagnostic Interview-Substance Abuse Module as the criterion standard.

205 Composite International Diagnostic Interview-Substance Abuse Module), yielding Diagnostic and Statist

206 ychiatric disorders including schizophrenia, substance abuse, mood disorders, Alzheimer's disease, an

207 function in the brain increases the risk for substance abuse, obesity, attention deficit/hyperactivit

208 dicted by long-term opioid therapy or active substance abuse (odds ratio [OR], 2.7; P < .001), age 65

209 ioral symptoms (e.g., cognitive deficits and substance abuse) often precede the clinical diagnosis of

210 ic stress disorder, depression, anxiety, and substance abuse) on this association.

211 t offending, and not largely attributable to substance abuse or antisocial personality disorder.

212 ICD symptoms, personal or family history of substance abuse or bipolar disorder, and a personality s

213 Adolescent substance abuse or dependence is largely a function of s

214 at 50% to 80% of prisoners have a history of substance abuse or dependence.

215 r co-occurring psychiatric disorders such as substance abuse or depression.

216 ical conditions but by confounding issues of substance abuse or homelessness.

217 In the EHR model, neither substance abuse (OR = 1.25; 95% CI = 0.70-2.21) nor depr

218 Conversely, in the PRO model, current substance abuse (OR = 2.78; 95% CI = 1.33-5.81) and curr

219 premorbid mood disorders, anxiety disorders, substance abuse, or alcohol abuse.

220 xcluded those with a history of head injury, substance abuse, or clinical depression.

221 ing or new psychiatric disorders, alcohol or substance abuse, or eating disorders.

222 rlying psychiatric disorder, the presence of substance abuse, or even the use of certain psychiatric

223 llness trajectory, chronicity, medication or substance abuse, or in fact a combination of some or all

224 proposed to improve depressive symptoms and substance abuse outcomes.

225 Univariate analysis suggested history of substance abuse (P < 0.001), anxiety (P = 0.01), depress

226 acy in preclinical models of anxiety, cough, substance abuse, pain (spinal and peripheral), and urina

227 emotional abuse; emotional neglect; parental substance abuse; parental mental illness or suicide atte

228 s in clinical domains are also discussed for substance abuse, Parkinson's disease, attention-deficit/

229 pical antidepressant receiving attention for substance abuse pharmacotherapy, and its action includes

230 have clinical utility for pain treatment and substance abuse pharmacotherapy.

231 l risk factors such as smoking, obesity, and substance abuse play a part but do not fully explain the

232 Although longer incisions and prior substance abuse predict higher likelihood of requesting

233 lizing problems, internalizing problems, and substance abuse problems, as well as for each of three c

234 o old or had nonhepatic comorbid conditions, substance abuse problems, or other psychosocial barriers

235 health conditions; a sad or depressed mood; substance abuse problems; medical problems; recent crise

236 t least one externalizing, internalizing, or substance abuse psychiatric problem (based on self- or p

237 Co-occurring substance abuse, psychosis, mania, and cognitive impairm

238 se is a major risk factor for mood, anxiety, substance abuse, psychotic, and personality disorders, a

239 ve class, carotid stenosis intervention, and substance abuse referral for alcohol.

240 higher incomes, younger ages, no testing at substance abuse rehabilitation centers, no recent syphil

241 esent potential targets for the treatment of substance abuse relapse, a psychiatric condition perpetu

242 ted factors and 1 only endorsed alcohol- and substance abuse-related factors; however, 7 classes of d

243 elplessness tests in rats without exhibiting substance abuse-related, gating, and sedative side effec

244 lective antagonists and partial agonists for substance abuse remains critically important but will al

245 communities may have with mental health and substance abuse research.

246 usual, which included a handout and list of substance abuse resources (n = 433).

247 vational interviewing, a handout and list of substance abuse resources, and an attempted 10-minute te

248 e curve=.659, p<.05, 95% CI .531, .786); the substance abuse risk estimate predicted its outcome with

249 oviders caring for persons with a history of substance abuse, risk-taking behavior, or suicidal ideat

250 tanding psychiatric disorders, in particular substance abuse, schizophrenia, and the potential antide

251 s in academic medical centers, and 5) making substance abuse screening and management routine care in

252 rences in the burden of chronic diseases and substance abuse seem to have major importance in explain

253 Increases in spending on mental health and substance abuse services after implementation of Oregon'

254 enditures per enrollee for mental health and substance abuse services attributable to parity were pos

255 ctions on how plans manage mental health and substance abuse services can improve insurance protectio

256 and visit limitations for mental health and substance abuse services that are not imposed on medical

257 ive parity on spending for mental health and substance abuse services.

258 ars despite minimal use of mental health and substance abuse services.

259 group had significantly higher prevalence of substance abuse, sexually transmitted diseases, decompen

260 factors, as well as reducing tobacco use and substance abuse, should be leading priorities in the med

261 ructive behavior, referral should be made to substance abuse specialists.

262 ta-analysis of five GABAA receptor genes and substance abuse support their involvement (with the best

263 use competencies into training, 2) assigning substance abuse teaching the same priority as teaching a

264 hology has been reported in individuals with substance abuse, temporal lobe epilepsy, amyotrophic lat

265 isposing factors for anxiety, depression, or substance abuse; that they play a key organizing role du

266 obiology contributes to eating disorders and substance abuse, this review focused on imaging studies

267 ion with WHO Department of Mental Health and Substance Abuse, this study (conducted in India, the UK,

268 as the contribution of chronic diseases and substance abuse to differences in bacteremia risk.

269 ould be screened for and counseled regarding substance abuse to facilitate a successful quit.

270 in the pathogenesis of HIV-1 resulting from substance abuse to provide a better understanding for th

271 lunteers recruited in the community and from substance abuse treatment centers included 6000 African

272 nary models such as community-based clinics, substance abuse treatment clinics, and specialized hospi

273 havioral therapy for depression delivered by substance abuse treatment counselors.

274 ating primary healthcare, mental health, and substance abuse treatment facilities, and highlights net

275 th substance abuse, few individuals entering substance abuse treatment have access to effective depre

276 nt depressive symptoms receiving residential substance abuse treatment is associated with improved de

277 s (n = 89; women n = 55) who volunteered for substance abuse treatment performed a Go/NoGo task while

278 not complete a 12-week cognitive behavioral substance abuse treatment program.

279 st drug use patterns among patients entering substance abuse treatment programs across the country wh

280 April 15, 2013, at 2 academic health center substance abuse treatment research sites.

281 e used data from the 2009 National Survey of Substance Abuse Treatment Services public use file and t

282 in source of data was the National Survey of Substance Abuse Treatment Services, which provides facil

283 ty law on expenditures for mental health and substance abuse treatment services.

284 Tailoring substance abuse treatment to specific needs of incarcera

285 ffectiveness trial that compared residential substance abuse treatment with residential treatment plu

286 ogy and behavior to inform research aimed at substance abuse treatment.

287 oid agonist therapy and improves outcomes of substance abuse treatment.

288 Secondary outcomes were admission to substance abuse treatment; ASI composite scores for medi

289 rug-diversion investigators, poison centers, substance-abuse treatment centers, and college students.

290 , with consequences for scientific research, substance-abuse treatment, and public policy.

291 Relapse is highly prevalent following substance abuse treatments, highlighting the need for im

292 adults and often associated with additional substance abuse, underscoring the importance of drug and

293 l in relationships, and (4) partner factors (substance abuse, unemployment, and infidelity).

294 nagement of traditional CAD risk factors and substance abuse, vitamin D deficiency should be evaluate

295 EHR vs PRO diagnosis of current substance abuse was 13% (n = 99) vs 6% (n = 45) (P < .00

296 Increased vulnerability to substance abuse was also demonstrated.

297 education and income), chronic diseases, and substance abuse was retrieved from public and medical re

298 Severely suicidal patients without substance abuse were randomly assigned to receive either

299 d risk assessment for unauthorised leave and substance abuse where its performance is relatively unte

300 interval [CI], 2.4- 17.5), those with active substance abuse within the past year (OR 2.2; 95% CI 1.4